Categories: Endocrine diseases

Aliases & Classifications for Hyperandrogenism

MalaCards integrated aliases for Hyperandrogenism:

Name: Hyperandrogenism 12 73 54 44 15 17 70
Hyperandrogenization Syndrome 12


External Ids:

Disease Ontology 12 DOID:11613
MeSH 44 D017588
SNOMED-CT 67 237793004
UMLS 70 C0206081

Summaries for Hyperandrogenism

MalaCards based summary : Hyperandrogenism, also known as hyperandrogenization syndrome, is related to adrenal cortical adenoma and cortisone reductase deficiency. An important gene associated with Hyperandrogenism is CYP21A2 (Cytochrome P450 Family 21 Subfamily A Member 2), and among its related pathways/superpathways are Aldosterone synthesis and secretion and mTOR signaling pathway (KEGG). The drugs Polyestradiol phosphate and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include ovary, skin and pituitary, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Hyperandrogenism is a medical condition characterized by high levels of androgens in females. Symptoms... more...

Related Diseases for Hyperandrogenism

Diseases related to Hyperandrogenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 335)
# Related Disease Score Top Affiliating Genes
1 adrenal cortical adenoma 31.9 POMC CYP21A2 CYP17A1 CYP11A1
2 cortisone reductase deficiency 31.7 SRD5A1 POMC HSD11B1 CYP21A2
3 precocious puberty, male-limited 31.4 POMC GNRH1 CYP21A2 CYP19A1
4 acanthosis nigricans 30.8 SHBG PRL INSR INS IGF1 ADIPOQ
5 adenoma 30.6 PRL POMC IGF1 CYP21A2
6 precocious puberty 30.5 GNRH1 CYP21A2 CYP19A1
7 luteoma 30.5 SHBG CYP21A2 CYP19A1
8 lipid metabolism disorder 30.5 SHBG INSR INS HSD11B1 CYP21A2 ADIPOQ
9 3-beta-hydroxysteroid dehydrogenase deficiency 30.4 HSD3B2 CYP21A2
10 hyperinsulinism 30.4 SHBG INSR INS IGFBP3 IGFBP1 IGF1
11 alopecia 30.4 SRD5A1 SHBG PRL IGF1 AR
12 ovarian cyst 30.3 PRL GNRH1 CYP19A1
13 leydig cell tumor 30.2 PRL GNRH1 CYP21A2 CYP19A1 CYP17A1 CYP11A1
14 aromatase deficiency 30.2 INS GNRH1 CYP19A1
15 hyperprolactinemia 30.2 SHBG PRL POMC INS IGF1 GNRH1
16 galactorrhea 30.2 PRL IGF1
17 acne 30.2 SRD5A1 SHBG PRL POMC INS IGF1
18 hyperglycemia 30.1 INSR INS IGF1 ADIPOQ
19 sleep apnea 30.1 INS IGF1 ADIPOQ
20 amenorrhea 30.1 WNT4 SHBG PRL POMC INS IGF1
21 adrenal adenoma 30.1 POMC INS HSD11B1 CYP21A2 CYP17A1 CYP11A1
22 central precocious puberty 30.0 IGFBP3 IGF1 GNRH1
23 pituitary tumors 30.0 PRL POMC IGF1
24 intracranial hypertension 30.0 PRL HSD11B1 ADIPOQ
25 hyperthyroidism 30.0 SHBG PRL POMC INS IGF1
26 insulin-like growth factor i 30.0 SHBG PRL INSR INS IGFBP3 IGFBP1
27 endometrial hyperplasia 30.0 CYP19A1 CYP17A1 AR
28 type 1 diabetes mellitus 29.9 INSR INS IGFBP3 IGFBP1 IGF1 ADIPOQ
29 hermaphroditism 29.9 WNT4 SHBG AR
30 alopecia, androgenetic, 1 29.9 SRD5A1 SHBG CYP21A2 CYP19A1 AR
31 donohue syndrome 29.9 INSR INS IGFBP3 IGF1
32 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 29.9 POMC CYP21A2
33 androgenic alopecia 29.8 SRD5A1 SHBG PRL INS IGF1 CYP19A1
34 estrogen excess 29.7 SHBG PRL GNRH1 CYP19A1
35 adrenal carcinoma 29.7 POMC HSD3B2 CYP21A2 CYP17A1 CYP11A1
36 pre-eclampsia 29.7 INS IGFBP3 IGFBP1 IGF1 ADIPOQ
37 laron syndrome 29.7 IGFBP3 IGFBP1 IGF1 ADIPOQ
38 sleep disorder 29.7 PRL POMC INS IGF1 ADIPOQ
39 glucose intolerance 29.7 SHBG PRL POMC INSR INS IGFBP1
40 pituitary adenoma 29.7 PRL POMC IGF1 GNRH1
41 endometriosis 29.7 WNT4 IGFBP1 GNRH1 CYP19A1 CYP17A1
42 infertility 29.7 SHBG PRL INS IGFBP1 GNRH1 CYP21A2
43 lipoid congenital adrenal hyperplasia 29.6 SRD5A1 POMC HSD3B2 GNRH1 CYP21A2 CYP19A1
44 anovulation 29.5 SRD5A1 SHBG PRL INS IGFBP3 IGFBP1
45 hypoglycemia 29.5 PRL POMC INSR INS IGFBP3 IGFBP1
46 cardiovascular system disease 29.5 SHBG INS IGFBP1 IGF1 HSD11B1 ADIPOQ
47 gestational diabetes 29.5 SHBG INSR INS IGFBP1 CAPN10 ADIPOQ
48 hypogonadism 29.4 SHBG PRL INS IGF1 GNRH1 AR
49 breast disease 29.2 SHBG PRL POMC IGFBP3 IGFBP1 IGF1
50 hypogonadotropic hypogonadism 29.2 SHBG PRL INS GNRH1 CYP19A1 AR

Graphical network of the top 20 diseases related to Hyperandrogenism:

Diseases related to Hyperandrogenism

Symptoms & Phenotypes for Hyperandrogenism

GenomeRNAi Phenotypes related to Hyperandrogenism according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.4 INSR
2 Decreased viability GR00221-A-2 9.4 INSR
3 Decreased viability GR00221-A-3 9.4 INSR
4 Decreased viability GR00221-A-4 9.4 INSR
5 Decreased viability GR00249-S 9.4 CYP17A1 IGFBP3 SRD5A1
6 Decreased viability GR00386-A-1 9.4 HSD3B2 POMC SRD5A1
7 Decreased viability GR00402-S-2 9.4 CAPN10 IGFBP3

MGI Mouse Phenotypes related to Hyperandrogenism:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.39 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 GNRH1
2 growth/size/body region MP:0005378 10.37 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
3 behavior/neurological MP:0005386 10.36 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
4 cellular MP:0005384 10.34 ADIPOQ AR CYP11A1 CYP17A1 CYP19A1 HSD11B1
5 cardiovascular system MP:0005385 10.31 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
6 immune system MP:0005387 10.31 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 CYP21A2
7 adipose tissue MP:0005375 10.3 ADIPOQ AR CAPN10 CYP17A1 CYP19A1 HSD11B1
8 homeostasis/metabolism MP:0005376 10.3 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
9 hematopoietic system MP:0005397 10.29 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 CYP21A2
10 integument MP:0010771 10.18 ADIPOQ AR CYP19A1 CYP21A2 GNRH1 HSD11B1
11 liver/biliary system MP:0005370 10.18 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 GNRH1
12 nervous system MP:0003631 10.1 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 GNRH1
13 muscle MP:0005369 9.97 ADIPOQ AR CYP11A1 CYP19A1 HSD11B1 IGF1
14 renal/urinary system MP:0005367 9.85 ADIPOQ AR CAPN10 CYP19A1 GNRH1 IGF1
15 reproductive system MP:0005389 9.7 AR CYP11A1 CYP17A1 CYP19A1 GNRH1 IGF1
16 skeleton MP:0005390 9.36 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1

Drugs & Therapeutics for Hyperandrogenism

Drugs for Hyperandrogenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Polyestradiol phosphate Approved Phase 4 28014-46-2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
Drospirenone Approved Phase 4 67392-87-4 68873
Topiramate Approved Phase 4 97240-79-4 5284627
8 Estradiol 3-benzoate Phase 4
9 Contraceptives, Oral, Combined Phase 4
10 Estradiol 17 beta-cypionate Phase 4
11 Estrogens Phase 4
12 Androgen Antagonists Phase 4
13 Mineralocorticoids Phase 4
14 Mineralocorticoid Receptor Antagonists Phase 4
15 diuretics Phase 4
16 Diuretics, Potassium Sparing Phase 4
17 Cyproterone acetate, ethinyl estradiol drug combination Phase 4
18 Hemostatics Phase 4
19 Drospirenone and ethinyl estradiol combination Phase 4
20 Contraceptive Agents Phase 4
21 Contraceptives, Oral Phase 4
Cyproterone Phase 4 2098-66-0 5284537
23 Contraceptive Agents, Male Phase 4
24 Calcium, Dietary Phase 4
25 Hypoglycemic Agents Phase 4
26 Follicle Stimulating Hormone Phase 4
27 Anticonvulsants Phase 4
Calcium Nutraceutical Phase 4 7440-70-2 271
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
30 Antibiotics, Antitubercular Phase 3
31 Antimalarials Phase 3
32 Matrix Metalloproteinase Inhibitors Phase 3
33 Anti-Bacterial Agents Phase 3
34 Antiparasitic Agents Phase 3
35 Anti-Infective Agents Phase 3
36 Antiprotozoal Agents Phase 3
Pioglitazone Approved, Investigational Phase 1, Phase 2 111025-46-8 4829
Ferrous fumarate Approved Phase 2 141-01-5
Norethindrone Approved Phase 2 68-22-4 6230
Orlistat Approved, Investigational Phase 2 96829-58-2 3034010
Inositol Approved, Investigational, Withdrawn Phase 2 87-89-8
Pancrelipase Approved, Investigational Phase 2 53608-75-6
Metformin Approved Phase 2 657-24-9 4091 14219
Sodium citrate Approved, Investigational Phase 2 68-04-2
Methyltestosterone Approved Phase 2 58-18-4 6010
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0
Testosterone enanthate Approved Phase 2 315-37-7 9416
Ibuprofen Approved Phase 2 15687-27-1 3672
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
Inulin Approved, Investigational, Nutraceutical Phase 2 9005-80-5 24763

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
2 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
3 The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
4 Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
5 Ovarian Function in Women With Polycystic Ovary Syndrome Recruiting NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
6 Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome: a Double-blind Placebo-controlled Clinical Trial Recruiting NCT04453306 Phase 4 Topiramate;Placebo
7 Pretreatment With Myo-inositol in Hyperandrogenic PCOS Patients Undergoing ART: a Randomized Controlled Trial Unknown status NCT03767569 Phase 3 Myo-inositol;Folic Acid
8 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women: A Randomized Trial Completed NCT00413179 Phase 3 Metformin;Clomiphene citrate;Placebo
9 The Use of an MMP Inhibitor, Doxycycline, to Reduce Ovarian Androgen Production and Restore Normal Cycling in Women With Polycystic Ovarian Syndrome Completed NCT01788215 Phase 3 doxycycline
10 Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism Unknown status NCT03757923 Phase 1, Phase 2 TAB METFORMIN;TAB PIOGLITAZONE
11 Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism Completed NCT00004763 Phase 2 leuprolide;Ethinyl estradiol/norethindrone
12 A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome Completed NCT03152591 Phase 2 LIK066;Placebo
13 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2 leuprolide acetate;spironolactone
14 Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women Completed NCT00704912 Phase 2 Orlistat/Meal Replacement/Lifestyle Modification;Loestrin 1/20;Combination of treatments
15 Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women Recruiting NCT01889199 Phase 2 Flutamide
16 Inositol Supplementation to Treat Polycystic Ovary Syndrome: A Double Blind Dose Ranging RCT (INSUPP-PCOS) Recruiting NCT03864068 Phase 2 Inositol
17 Acupuncture or Metformin for Insulin Resistance in Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial Recruiting NCT02647827 Phase 2 Metformin
18 Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial Enrolling by invitation NCT02523898 Phase 2 metformine;placebo;clomiphene citrate
19 The Effect of Ibuprofen on the Endocrine and Metabolic Status of Women With PCOS. Enrolling by invitation NCT04485403 Phase 2 Ibuprofen
20 Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin in Hyperandrogenic Lean PCOS Women Recruiting NCT02244567 Phase 1 Metformin 850 mg twice daily for 3 months
21 Suppression of Daytime and Nighttime LH Frequency by Progesterone in Early Pubertal Girls With and Without Hyperandrogenemia (JCM024) Recruiting NCT01428089 Phase 1 Progesterone;Placebo
22 Evaluation of the Ovarian Dynamic Response and the Inflammatory Response to Oral Lipid Challenge in Relation to Body Composition in Polycystic Ovary Syndrome Terminated NCT01489319 Phase 1 Salsalate;Salsalate
23 Influence of Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome Unknown status NCT01569425
24 Influence of Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome Unknown status NCT01711476
25 Ultrasound Three-dimensional Characterization of Ovarian Morphology in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT02402413
26 Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome - a Study on Multigenerational Families Unknown status NCT00665171
27 Effects of Myo-inositol, Alpha-Lactalbumin and Folic Acid Treatment in PCOS Women of Mexico and Italy Completed NCT04645745
28 Androgen Metabolism and Reproductive Outcome Completed NCT02106676
29 Use of Osteopathic Principles for Nonpharmacologic, Therapeutic Interventions in Women With Polycystic Ovary Syndrome Completed NCT03383484
30 Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study Completed NCT01526616 Metformin;Metformin plus Spironolactone
31 Circulating Androgen Levels Are Not Affected by the Administration of Vaginal Micronized Progesterone for Withdrawal Bleeding in Patients With Polycystic Ovarian Syndrome Completed NCT03088046 Micronized Progesterone
32 Effects of Oral Androgen Administration on Hyperglycemia-Induced Inflammation in Lean Reproductive-Age Women Completed NCT01753037
33 Effect of Free Fatty Acids on Androgen Precursors in Vivo in Healthy Young Women Completed NCT00473603 lipid/heparin infusion
34 Effect of Decreasing Iron Tissue Depots on the Cardiovascular Risk of Women With Polycystic Ovary Syndrome Completed NCT02460445 ethinylestradiol;Cyproterone Acetate
35 Clinical and Biochemical Presentations of Distinctive Types of Biochemical Hyperandrogenism in Premenopausal Taiwanese Women Completed NCT01940666
36 Obesity and Clinical Presentation of Hyperandrogenism Completed NCT01114633
37 A Study of Clinical Presentation and Cardiovascular Disease of Hyperandrogenism and Polycystic Ovary Syndrome in Obese and Non-obese Taiwanese Women Completed NCT01113918
38 Health-related Quality of Life, Sexuality and Hormone Status After Bariatric Surgery Completed NCT03188640
39 Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025) Completed NCT01427595 Metformin;Progesterone;estrace
40 Adrenal Hyperplasia Among Young Patients With Polycystic Ovarian Syndrome Completed NCT01313455
41 Effects of Combined Therapy With Myo-inositol and Alpha-Lipoic Acid on Clinical, Endocrine and Metabolic Features in Women Affected by Polycystic Ovary Syndrome Completed NCT02651636 myo-inositol,alpha-lipoic acid and folic acid
42 Does Spironolactone Normalize Sleep-wake Luteinizing Hormone (LH) Pulse Frequency in Pubertal Girls With Hyperandrogenism? (CBS010) Recruiting NCT04723862 Early Phase 1 Spironolactone;Placebo
43 Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age Recruiting NCT03905941 Early Phase 1 Metformin;Oral combined hormonal contraceptives
44 Study to Evaluate if Androgen-receptor Blockade (Spironolactone) Improves Progesterone-suppression of Wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism Recruiting NCT03068910 Early Phase 1 Micronized progesterone;Spironolactone;Placebo
45 Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess? Recruiting NCT04075149 Early Phase 1 Spironolactone
46 Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS Recruiting NCT03905603 Early Phase 1 ACTH;rhCG
47 Study to Assess Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism Recruiting NCT00929006 Early Phase 1 Micronized progesterone suspension;Placebo
48 Dissecting Androgen Excess and Metabolic Dysfunction for an Integrated Systems Approach to Polycystic Ovary Syndrome Through the Assessment of Detailed Phenome and Metabolome Data Recruiting NCT03911297
49 Health of Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study Recruiting NCT03742011
50 Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess (CBS006) Recruiting NCT01422759 Spironolactone

Search NIH Clinical Center for Hyperandrogenism

Cochrane evidence based reviews: hyperandrogenism

Genetic Tests for Hyperandrogenism

Anatomical Context for Hyperandrogenism

MalaCards organs/tissues related to Hyperandrogenism:

Ovary, Skin, Pituitary, Bone, Liver, Breast, Prostate

Publications for Hyperandrogenism

Articles related to Hyperandrogenism:

(show top 50) (show all 3942)
# Title Authors PMID Year
Premature pubarche in Mediterranean girls: high prevalence of heterozygous CYP21 mutation carriers. 61 54
20059433 2010
Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance and clinical parameters. 61 54
20388053 2010
[Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome]. 61 54
20450755 2010
Detection and management of late-onset 21-hydroxylase deficiency in women with hyperandrogenism. 54 61
20070950 2010
Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. 61 54
20015405 2009
Response of IGF and IL-6 to ovarian stimulation in PCOS and normal women. 61 54
19938957 2009
[Increased level of prostate-specific antigen: a diagnostic marker of hyperandrogenism women]. 61 54
20218317 2009
Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. 61 54
19552904 2009
Genetic polymorphisms of GnRH and gonadotrophic hormone receptors affect the phenotype of polycystic ovary syndrome. 54 61
19403562 2009
Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. 54 61
19401323 2009
Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism. 61 54
19401444 2009
The role of genetic variation in the lamin a/c gene in the etiology of polycystic ovary syndrome. 61 54
19401371 2009
KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women. 61 54
19366843 2009
A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. 54 61
18851710 2009
The frequency of CYP 21 gene mutations in Turkish women with hyperandrogenism. 61 54
19085698 2009
Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. 54 61
19345914 2009
[Effect of anti-Müllerian hormone on P450 aromatase mRNA expression in cultured human luteinized granulose cells]. 61 54
19570444 2009
Nonhuman primates as models for human adrenal androgen production: function and dysfunction. 61 54
18683055 2009
An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. 54 61
19215335 2009
Effects of growth hormone reduction in a patient with polycystic ovary syndrome complicated with acromegaly. 54 61
18840925 2009
Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. 61 54
19078868 2008
Polycystic ovary syndrome: treatment strategies and management. 61 54
19013863 2008
Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome. 61 54
18377903 2008
Cardiovascular risk in women with polycystic ovary syndrome. 61 54
18799960 2008
Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age < or =14 years, 13 with precocious puberty, 23 with a first-degree relative with polycystic ovary syndrome. 61 54
19209619 2008
Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. 61 54
18602948 2008
Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. 61 54
18639784 2008
Insulin receptor autoimmunity and insulin resistance. 61 54
18556968 2008
Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. 54 61
18362299 2008
Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. 61 54
18382906 2008
Polycystic ovary syndrome and oocyte developmental competence. 54 61
18081939 2008
Implications of polycystic ovary syndrome on oocyte development. 61 54
18181083 2008
[Polymorphism in CYP11alpha and CYP17 genes and the etiology of hyperandrogenism in patients with polycystic ovary syndrome]. 54 61
18499961 2008
Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus. 54 61
17895317 2007
Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. 61 54
17825390 2007
Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 54 61
17885806 2007
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. 54 61
17984248 2007
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. 54 61
17954415 2007
Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. 54 61
17710731 2007
Phenotypic characteristics according to insulin sensitivity in non-obese Korean women with polycystic ovary syndrome. 61 54
17606307 2007
Association of the GAA1013-->GAG polymorphism of the insulin-like growth factor-1 receptor (IGF1R) gene with premature pubarche. 61 54
17442315 2007
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. 61 54
17582143 2007
Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. 54 61
17356050 2007
Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. 54 61
17374711 2007
Lack of association between common polymorphisms in the 17beta-hydroxysteroid dehydrogenase type V gene (HSD17B5) and precocious pubarche. 54 61
17583494 2007
Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. 61 54
17138841 2007
Low-dose glucocorticoids in hyperandrogenism. 61 54
17628912 2007
Childhood obesity and insulin resistance. 61 54
17709876 2007
Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. 54 61
17426408 2007
Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome. 54 61
17067587 2006

Variations for Hyperandrogenism

Expression for Hyperandrogenism

Search GEO for disease gene expression data for Hyperandrogenism.

Pathways for Hyperandrogenism

Pathways related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.2 WNT4 SRD5A1 IGF1 AR
Show member pathways
7 11.76 POMC HSD3B2 CYP21A2 CYP11A1
Show member pathways
Show member pathways
11.53 SRD5A1 HSD3B2 HSD11B1 CYP21A2 CYP19A1 CYP17A1
Show member pathways
11.48 HSD3B2 CYP19A1 CYP17A1
12 11.43 PRL INSR INS
13 11.38 IGF1 CYP19A1 AR
14 11.27 INSR INS IGF1
15 11.21 INSR INS IGF1 HSD3B2 CYP19A1 CYP17A1
16 11.16 PRL HSD11B1 CYP11A1
Show member pathways
11.13 SRD5A1 POMC HSD3B2 HSD11B1 CYP21A2 CYP19A1
Show member pathways
10.98 SRD5A1 CYP21A2 CYP17A1
19 10.96 IGFBP3 IGFBP1 IGF1
20 10.91 PRL POMC INS
21 10.84 SHBG GNRH1 AR

GO Terms for Hyperandrogenism

Cellular components related to Hyperandrogenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 WNT4 PRL POMC INS IGFBP3 IGFBP1
2 extracellular region GO:0005576 9.96 WNT4 SHBG PRL POMC INS IGFBP3
3 endoplasmic reticulum lumen GO:0005788 9.67 WNT4 INS IGFBP3 IGFBP1
4 insulin-like growth factor ternary complex GO:0042567 9.16 IGFBP3 IGF1
5 insulin-like growth factor binding protein complex GO:0016942 8.96 IGFBP3 IGF1
6 organelle membrane GO:0031090 8.92 SRD5A1 CYP21A2 CYP19A1 CYP17A1

Biological processes related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.05 PRL INSR INS IGF1 AR
2 oxidation-reduction process GO:0055114 10.02 SRD5A1 HSD3B2 HSD11B1 CYP21A2 CYP19A1 CYP17A1
3 cell-cell signaling GO:0007267 9.93 POMC INS GNRH1 AR
4 glucose homeostasis GO:0042593 9.86 POMC INSR INS ADIPOQ
5 cellular protein metabolic process GO:0044267 9.85 PRL INS IGFBP3 IGFBP1 IGF1
6 cellular response to insulin stimulus GO:0032869 9.84 SRD5A1 INSR CAPN10 ADIPOQ
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 INSR INS IGF1
8 insulin receptor signaling pathway GO:0008286 9.82 INSR INS IGFBP1
9 negative regulation of tumor necrosis factor production GO:0032720 9.8 POMC IGF1 ADIPOQ
10 activation of protein kinase B activity GO:0032148 9.75 INSR INS IGF1
11 positive regulation of mitotic nuclear division GO:0045840 9.72 INSR INS IGF1
12 steroid metabolic process GO:0008202 9.72 SRD5A1 HSD11B1 CYP21A2 CYP17A1 CYP11A1
13 sterol metabolic process GO:0016125 9.7 CYP21A2 CYP19A1 CYP11A1
14 sex differentiation GO:0007548 9.69 WNT4 SRD5A1 CYP17A1
15 positive regulation of glycolytic process GO:0045821 9.67 INSR INS IGF1
16 cellular response to epinephrine stimulus GO:0071872 9.65 SRD5A1 ADIPOQ
17 positive regulation of MAPK cascade GO:0043410 9.65 INSR INS IGFBP3 IGF1 AR
18 neuron projection maintenance GO:1990535 9.64 INSR INS
19 progesterone metabolic process GO:0042448 9.63 SRD5A1 CYP17A1
20 cellular response to testosterone stimulus GO:0071394 9.62 SRD5A1 AR
21 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.61 IGFBP3 IGFBP1
22 positive regulation of respiratory burst GO:0060267 9.61 INSR INS
23 positive regulation of glycogen biosynthetic process GO:0045725 9.61 INSR INS IGF1
24 C21-steroid hormone metabolic process GO:0008207 9.6 HSD3B2 CYP11A1
25 androgen catabolic process GO:0006710 9.59 SRD5A1 CYP19A1
26 mineralocorticoid biosynthetic process GO:0006705 9.58 HSD3B2 CYP21A2
27 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.58 IGFBP3 IGF1 AR
28 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.57 WNT4 AR
29 positive regulation of glucose import GO:0046326 9.55 INSR INS IGF1 CAPN10 ADIPOQ
30 androgen biosynthetic process GO:0006702 9.54 SRD5A1 HSD3B2 CYP17A1
31 steroid biosynthetic process GO:0006694 9.43 SRD5A1 HSD3B2 CYP21A2 CYP19A1 CYP17A1 CYP11A1
32 glucocorticoid biosynthetic process GO:0006704 9.02 HSD3B2 HSD11B1 CYP21A2 CYP17A1 CYP11A1

Molecular functions related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.91 WNT4 POMC IGFBP1 AR ADIPOQ
2 oxidoreductase activity GO:0016491 9.87 SRD5A1 HSD3B2 HSD11B1 CYP21A2 CYP19A1 CYP17A1
3 heme binding GO:0020037 9.78 CYP21A2 CYP19A1 CYP17A1 CYP11A1
4 iron ion binding GO:0005506 9.76 CYP21A2 CYP19A1 CYP17A1 CYP11A1
5 monooxygenase activity GO:0004497 9.73 CYP21A2 CYP19A1 CYP17A1 CYP11A1
6 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 CYP21A2 CYP19A1 CYP17A1 CYP11A1
7 insulin-like growth factor receptor binding GO:0005159 9.54 INSR INS IGF1
8 androgen binding GO:0005497 9.49 SHBG AR
9 insulin-like growth factor I binding GO:0031994 9.43 INSR IGFBP3 IGFBP1
10 insulin-like growth factor II binding GO:0031995 9.33 INSR IGFBP3 IGFBP1
11 steroid binding GO:0005496 9.26 SHBG HSD11B1 CYP21A2 AR
12 hormone activity GO:0005179 9.1 PRL POMC INS IGF1 GNRH1 ADIPOQ

Sources for Hyperandrogenism

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....